Skip to main content

Parabilis Medicines, Inc 10-Q for FY2026 Q3

Parabilis Medicines, Inc. (PBLS)

10-Q 2026-11-12 For: 2026-09-30
View Original
Added on November 12, 2026

About this 10-Q

Parabilis Medicines, Inc filed this 10-Q on November 12, 2026, covering the quarter ended September 30, 2026 (FY2026 Q3).

Net loss widened to $44.5 million for the three months ended September 30, 2026, from $33.5 million a year earlier. Research and development expense rose to $45.6 million, mainly from higher external costs for zolucatetide. Cash, cash equivalents and marketable securities totaled $1,072.9 million at September 30, 2026, which the company expects to fund operations into 2030. AI summary

Headline figures

Quarter ended September 30, 2026, as reported in this filing, compared with the same period a year earlier where the filing states it.

Revenue
$2.11M
compared with $0 a year earlier
Net loss
$44.49M
compared with a net loss of $33.48M a year earlier
Diluted EPS
-$0.36
compared with -$21.66 a year earlier